FLC News

NINDS

NINDS Deep TMS System1

This device is an invention for deep transcranial magnetic stimulation (TMS) produced by a noninvasive stimulator placed on a patient’s head to magnetically stimulate the brain. The unique coil shape is designed to target deep brain regions, like the nucleus accumbens. Stimulation using the device has no known long-term side effects or systemic effects, and is well-tolerated, with patients experiencing only mild side effects such as headaches.

The device was devised under collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA), and Tel-Aviv University scientists. Later, NINDS helped develop improvements that enabled in-depth simulation, selectively allowing the targeting of brain structures such as the amygdala, nucleus accumbens, and basal ganglia. The NINDS Human Motor Control Section researches the physiology of human voluntary movement and the pathophysiology of different movement disorders, and TMS is one of its major techniques.

Exclusively licensed and marketed by Brainsway, Ltd., an Israeli company, the device is marketed in the United States for major depressive disorder and can be prescribed after failure of conventional drug therapy. The device is also applicable for post-traumatic stress disorder (PTSD), with possible further promise for treatment of other neurophysiological conditions associated with deep regions of the brain. It has been studied in 60 clinical studies at leading institutions worldwide, and is marketed in Europe and South America for bipolar depression, PTSD, schizophrenia (negative symptoms), chronic pain, and Parkinson’s disease.

Category: 
FLC News